MedTrace Logo

Affective Dysregulation (AD) in Children With ADHD Treated by Guanfacin

NCT04016207 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2020-04-06

No results posted yet for this study

Summary

Early onset, high prevalence and persistence, as well as developmental comorbidity make affective dysregulation (AD) in childhood one of the most psychosocially impairing and cost-intensive mental conditions. Despite continuous research, there is still a substantial need for optimization of individual treatment strategies in order to improve outcomes and to reduce subjective and economic burden. Here we want to study the change of psychopathological markers of affective dysregulation (AD) treatment of affective dysregulation (AD) in children with Attention Deficit Hyperactivity Disorder (ADHD) treated by Guanfacine. These children did not respond to methylphenidate treatment. The results will allow the generation of a hypothesis for a randomized clinical trial to investigate the efficacy and safety of Guanfacine for the treatment of AD in children.

Conditions

  • Affective Dysregulation

Interventions

DRUG

Guanfacine

regular treatment

Sponsors & Collaborators

  • Prof. Dr. Veit Roessner and PD Dr. Robert Waltereit jointly lead and conduct the study

    collaborator UNKNOWN

  • Technische Universität Dresden

    lead OTHER

Principal Investigators

  • Veit Roessner, MD · Technical University Dresden, Child and Adolescent Psychiatry

Eligibility

Min Age
6 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-01
Primary Completion
2021-03-31
Completion
2021-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04016207 on ClinicalTrials.gov